Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era

Bladder compliance is a measure of distensibility. Maladies such as myelodysplasia, myelomeningocele, spinal cord injury, multiple sclerosis and obstructive uropathy are known to decrease bladder compliance. Decrease in bladder compliance is a characteristic of neurogenic bladders. The pathophysiolo...

Full description

Saved in:
Bibliographic Details
Published in:Current urology reports 2017-08, Vol.18 (8), p.64-64, Article 64
Main Authors: Prakash, Nachiketh Soodana, Lopategui, Diana M., Gomez, Christopher
Format: Article
Language:English
Subjects:
Botulinum Toxins, Type A - adverse effects
Botulinum Toxins, Type A - therapeutic use
Compliance
Humans
Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu
Medicine
Medicine & Public Health
Nephrology
Neuromuscular Agents - adverse effects
Neuromuscular Agents - therapeutic use
Section Editor
Topical Collection on Lower Urinary Tract Symptoms & Voiding Dysfunction
Urinary Bladder Diseases - drug therapy
Urinary Bladder Diseases - physiopathology
Urodynamics - drug effects
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bladder compliance is a measure of distensibility. Maladies such as myelodysplasia, myelomeningocele, spinal cord injury, multiple sclerosis and obstructive uropathy are known to decrease bladder compliance. Decrease in bladder compliance is a characteristic of neurogenic bladders. The pathophysiology of bladder compliance is complex but ultimately leads to high pressure during filling and storage phases. These high pressures lead to renal impairment, incontinence, and recurrent urinary tract infections. This review presents management of poorly compliant bladders with onabotulinumtoxinA.
ISSN:1527-2737
1534-6285
DOI:10.1007/s11934-017-0707-6